Therapeutically useful synthetic oligonucleotides

Details Therapeutically useful synthetic oligonucleotides Therapeutically useful synthetic oligonucleotides

2007-01-02

2007-01-02

Zara, Jane (Department: 1635)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Carbohydrate doai

C424S009100, C424S009200, C435S006120, C435S091100, C435S455000, C514S001000, C514S002600, C536S023100, C536S024100, C536S024330

Reexamination Certificate

active

09735363

ABSTRACT:
The present invention provides a composition and method comprising a 2–20 base 3′-OH, 5′-OH synthetic oligonucleotide (sequence) selected from the group consisting of (GxTy)n, (TyGx)n, a(GxTy)n, a(TyGx)n, (GxTy)nb, (TyGx)nb, a(GxTy)nb, a(TyGx)nb, wherein x and y is an integer between 1 and 7, n is an integer between 1 and 12, a and b are one or more As, Cs, Gs or Ts and wherein the sequence induces a response selected from the group consisting of induction of cell cycle arrest, inhibition of proliferation, activation of caspases and induction of apoptosis in cancer cells and production of cytokines by immune system cells.

REFERENCES:
patent: 4983518 (1991-01-01), Schaffner et al.
patent: 5474796 (1995-12-01), Brennan
patent: 5582981 (1996-12-01), Toole et al.
patent: 5861245 (1999-01-01), McClelland et al.
patent: 6211431 (2001-04-01), Boevink et al.
patent: 6255473 (2001-07-01), Vitek et al.
patent: WO 94 08053 (1994-04-01), None
patent: WO 96 23508 (1996-08-01), None
patent: WO 96/39500 (1996-12-01), None
patent: WO 97 20924 (1997-06-01), None
patent: WO 97/20924 (1997-06-01), None
Promega Catalogue (1998).
Boehringer Mannheim Catalogue (1997).
Peracchi, A., Rev. Med. Virol., vol. 14, pp. 47-64 (2004).
Chirila, T.V. et al., Biomaterials, vol. 23, pp. 321-342 (2002).
Branch, A., Trends in Biochem. Sci., vol. 23, pp. 45-50 (1998).
Agrawal, S. et al., Molecular Med. Today, vol. 6, pp. 72-81 (2002).
Crooke, S.T., antisense Research and Application, Chapter 1, pp. 1-50, Ed. by S. Crooke, Publ. by Springer-Verlag (1998).
Bates et al., “Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding,” The Journal of Biological Chemistry, vol. 274, No. 37, Sep. 10, 1999, pp. 26369-26377.
Morassutti et al., “Nucleosides & Nucleotides,” 18(6&7), pp. 1711-1716 (1999).
Scaggiante et al., “Human cancer cells lines growth inhibition by GTηoligodeoxyribonucleotides recognizing single-stranded DNA-binding proteins,” European Journal of Biochemistry, vol. 252, pp. 207-215, 1998.
Ballas et al., “Induction of NK Activity in Murine and Human Cells by CpG Motifs in Oligodeoxynucleotides and Bacterial DNA,” J. Immunol., Sep. 1, 1996, p. 1840-1845, vol. 157.
Bates et al., “Antiproliferative Activity of G-rich Oligonucleotides Correlates with Protein Binding,” J. Biol. Chem., Sep. 10, 1999, vol. 274, pp. 26369-26377.
Braun et al., “Cytotoxic T Cells Deficient in Both Functional Fas Ligand and Perforin Show Residual Cytolytic Activity yet Lose Their Capacity to Induce Lethal Acute Graft-Versus-Host Disease,” J. Exp. Med., 1996, p. 657-661, vol. 183.
Famularo et al., “Fas/Fas Ligand on the Road; An Apoptotic Pathway Common to AIDS, Autoimmunity, Lymphoproliferation and Transplantation,” Med. Hypoth.,.1999, p. 50-62, vol. 53.
Filion, M.C. et al., “Inhibition of cell cycle progression and induction of apoptosis in leukemia cells byMycobacterium phleiDNA and derived synthetic oligonucleotides.” Clinical Cancer Research (Nov. 7-10, 2000), vol. 6, Supp.; p. 4571S.
Filion, M.C. et al., “Mycobacterium phleicell wall complex directly induces apoptosis in human bladder cancer cells.” British Journal of Cancer (Jan. 1999) 79(2) 229-35.
Filion, M.C., et al., “Modulation of interleukin-12 synthesis by DNA lacking the CpG motif and present in a mycobacterial cell wall complex.” Cancer Immunology Immunotherapy (Aug. 2000), 49(6), pp. 325-334.
Griffith, et al., “Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege,” Science, Nov. 17, 1995, vol. 270, pp. 1189-1192.
Hochhauser, D., “Modulation of chemosensitivity through altered expression of cell cycle regulatory genes in cancer,” Anti-Cancer Drugs, 1997, vol. 8, pp. 903-910.
Klinman et al., “CpG Motifs Present in Bacterial DNA Rapidly Induce Lymphocytes to Secrete Interleukin 6, Interleukin 12, and Interferon γ,” Proc. Natl. Acad. Sci. USA, Apr. 1996, pp. 2879-2883, vol. 93.
Kondo et al., “Essential Roles of the Fas Ligand in the Development of Hepatitis,” Nature Med., Apr. 1997, pp. 409-413, vol. 3, No. 4.
Lipford et al., “CpG-Containing Synthetic Oligonucleotides Promote B and Cytotoxic T Cell Responses to Protein Antigen: A New Class of Vaccine Adjuvants,” Eur. J. Immunol., 1997, pp. 2340-2344, vol. 27.
Morassutti, et al., “Correlation between cytotoxic effect and binding to nuclear proteins of oligomeric d(GT)n sequences in human cancer CCRF-CEM cell line,” Minerva Biotec, Jun. 1995, pp. 176-181.
Morassutti, et al., “Effect of Oligomer Length and Base Substitutions On The Cytotoxic Activity and Specific Nucelar Protein Recognition of GTn Oligonucleotides in the Human Leukemic CCRF-CEM Cell Line,” Nucleosides and Nucleotides, 18(6&7), pp. 1711-1716 (1999).
Nagata, S., “Fas Ligand-Induced Apoptosis,” Ann. Rev. Genet., 1999, pp. 29-55, vol. 33.
Nishioka et al., “An Augmentation of Fas (CD95/APO-1) Antigen Induced by Radiation: Flow Cytometry Analysis of Lymphoma and Leukemia Cell Lines,” Int. J. Mol. Med., 1999, pp. 275-278, vol. 3.
O'Connell, et al., “The Fas Counterattack: Fas-Mediated T Cell Killing by Colon Cancer Cells Expressing Fas Ligand,” J. Exp. Med., Sep. 1996, pp. 1075-1082, vol. 184.
Owen-Schaub et al., “Fas and Fas Ligand Interactions in Malignant Disease (Review),” Int. J. Oncol., 2000, pp. 5-12, vol. 17.
Promega Catalog 1993/94, Revolutions in Science, cover and pp. 90-91.
Reader, S., et al., “Identification of non-antisense phosphodiester oligonucleotides that induce cell cycle arrest and apoptosis in cancer cells.” Clinical Cancer Research (Nov. 7-10, 2000), vol. 6, Supp.; p. 4571S.
Sabelko-Downes et al., “The Role of Fas Ligandin vivoas a Cause and Regulator of Pathogenesis,” Curr. Opin. Immunol., Jun. 2000, pp. 330-335, vol. 12.
Scaggiante et al., “Human Cancer Cell Lines Growth Inhibition by GTηOligodeoxyribonucleotides Recognizing Single-Stranded DNA-Binding Proteins,” Eur. J. Biochem., Mar. 1, 1998, pp. 207-215, vol. 252.
Sheard et al., “UP-Regulation of FAS (CD95) in Human p53wild-typeCancer Cells Treated With Ionizing Radiation,” Int. J. Cancer, Nov. 27, 1997, pp. 757-762, vol. 73.
Vlassov et al., “Transport of Oligonucleotides across Natural and Model Membranes,” Biochem. Biophys. Acta., 1994, pp. 95-108, vol. 1197.
Wagner, R., “Gene Inhibition Using Antisense Oligodeoxynucleotides,” Nature, 1994, pp. 333-335, vol. 372.
Wang et al., “Unmethylated CpG Motifs Protect Murine B Lymphocytes Against Fas-Mediated Apoptosis,” Cellular Immunol., 1997, pp. 162-167, vol. 180.
Wyllie et al., “Cell Death: The Significance of Apoptosis,” Int. Rev. Cytol., 1980, pp. 251-306, vol. 68.
Wyllie A., “Glucocorticoid-Induced Thymocyte Apoptosis is Associated with Endogenous Endonuclease Activation,” Nature, 1980, pp. 555-556, vol. 284.
Yoong et al., “Fas/Fas Ligand Interaction in Human Colorectal Hepatic Metastases,” Am. J. Pathol., Mar. 1999, pp. 693-703, vol. 154.

Affiliated with

Also associated with

Rating

Therapeutically useful synthetic oligonucleotides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Therapeutically useful synthetic oligonucleotides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutically useful synthetic oligonucleotides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3815282